Skip to main content
. 2019 Dec 14;2019:8245810. doi: 10.1155/2019/8245810

Figure 6.

Figure 6

The MALAT1/miR-181b/TOX pathway is associated with the MAPK pathway. (a, b) Expression of pERK and pp38 after treating with MALAT1 shRNA and shRNA+inhibitor. P < 0.05 versus the control group. #P < 0.05 versus the shRNA group. (c, d) Expression of pERK and pp38 after treating with TOX siRNA and siRNA+inhibitor. P < 0.05 versus the control group; #P < 0.05 versus the siRNA group.